TX-MARY-KAY
23.6.2022 18:04:11 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skincare innovation, recently sponsored and revealed its inaugural Mary Kay Skin Health/Skin Disease Research Grants awardees for researchers conducting groundbreaking, innovative studies in skin health and skin disease at the 2022 Society for Investigative Dermatology (SID) Annual Meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220623005229/en/
“As a decades-long leader in global cosmetics and skincare innovation, Mary Kay remains committed to enriching women’s lives across the world,” said Dr. Lucy Gildea, Mary Kay’s Chief Innovation Officer, Product and Science, at the event. “We also have a steadfast commitment to producing the highest quality products and conducting breakthrough skin science research. We recognize collaboration is crucial to new discoveries, and partnerships with scientific, medical, and academic communities are vital collaborations—which is why we’re thrilled to award these scientific grants.”
The Mary Kay Skin Health/Skin Disease Research Grants were announced at last year’s meeting in partnership with SID. The $25,000 grants were to be awarded to four researchers conducting incredible work in skin research to uncover new perspectives and invention strategies. In the months following the 2021 SID meeting, the company received applications from scientists across the country.
The four grant awardees ultimately selected were:
- Dr. Allison C. Billi , MD, Ph.D., and Assistant Professor in the Dept of Dermatology at the University of Michigan. Dr. Billi’s primary research goal is to understand “what drives photoaging.” The grant will fund research to identify targetable pathways that help prevent or potentially reverse the effects of photoaging.
- Dr. Angel S. Byrd , MD, Ph.D. and Assistant Professor at Howard University College of Medicine and Adjunct Assistant Professor at JHUSOM (Departments of Dermatology). Dr. Byrd’s work focuses on the genetic basis of melasma. This grant will fund research to help discover unknown genetic causes of melasma to design personalized treatment options.
- Dr. Mae Alexandra Carpenter , Ph.D. Trainee at Wright State University. Dr. Carpenter’s work explores how damaged DNA-containing particles are released and how they activate inflammatory pathways. Funding this research will help develop new therapeutic approaches to reduce UVB photosensitivity in autoinflammatory diseases.
- Dr. Jennifer Powers , MD and Clinical Associate Professor in the Dept of Dermatology at the University of Iowa. Dr. Powers is interested in the influence of the microbiome and the healing environment on wound healing and scar formation. Funding for this research will help understand how the immune system and microbiota interact to modify scar formation from ulcers and surgical wounds.
“Congratulations to each of our 2022 grant award recipients,” added Dr. Gildea. “These individuals were carefully chosen in collaboration with the Society for Investigative Dermatology—and we are thrilled to support their research.”
The sponsorship and grants revealed at SID are just the latest efforts by Mary Kay to reinforce the company’s long-standing commitment to advancing skin health research and development. Mary Kay holds more than 1,600 patents for products, technologies, and packaging designs in its global portfolio.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com , find us on Facebook , Instagram , and LinkedIn , or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005229/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom